v3.25.4
Stock-Based Payments (Tables)
 9 Months Ended
Jan. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2026202520262025
General and administrative$352 $209 $692 $299 
Sales and marketing20 31 45 122 
Research and development35 2 99 9 
Cost of oncology revenue16 14 44 93 
Total stock-based compensation expense$423 $256 $880 $523 
Schedule of Valuation Assumptions For Stock Options
Black-Scholes and Monte Carlo assumptions used to calculate the fair value of Champions options granted by the Company during the three and nine months ended January 31, 2026 and 2025 were as follows:
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2026202520262025
Expected term in years
6
6
6
6
Risk-free interest rates
3.75% - 3.84%
4.09% - 4.34%
3.75% - 4.50%
3.58% - 4.48%
Volatility
54.94% - 56.31%
54.54% - 56.37%
54.94% - 62.00%
 54.54% - 62.72%
Dividend yield—%—%—%—%
Black-Scholes assumptions used to calculate the fair value of Corellia options granted by Corellia during May 2025 were as follows:

Nine Months Ended
January 31,
 20262025
Expected term in years60
Risk-free interest rates4.15%—%
Volatility65%—%
Dividend yield—%—%
Schedule of Stock Option Activity
The Company’s stock options activity for the 2021 and 2010 equity incentive plans for the nine months ended January 31, 2026 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20251,642,351 36,331 1,678,682 $4.98 4.9$4,434,000 
Granted1,103,972 — 1,103,972 7.17 9.5
Exercised(109,656)— (109,656)2.13 
Forfeited(58,625)— (58,625)7.65   
Canceled(12,375)— (12,375)7.26 
Expired(53,333)— (53,333)11.96   
Outstanding, January 31, 20262,512,334 36,331 2,548,665 $5.83 6.6$4,556,000 
Vested and expected to vest as of January 31, 20262,512,334 36,331 2,548,665 $5.83 6.6$4,556,000 
Exercisable as of January 31, 20261,426,449 7,500 1,433,949 $4.83 4.4$4,000,000 
    
The stock options activity for the Corellia 2023 Global equity incentive plan for the nine months ended January 31, 2026 was as follows:
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 2025— — — $— $— $— 
Granted300 — 300 $1,682.00 9.30
Outstanding, January 31, 2026300 — 300 $1,682.00 9.30$110,000 
Vested and expected to vest as of January 31, 2026300 — 300 $1,682.00 9.30$110,000 
Exercisable as of January 31, 2026— — — $— — $—